Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Bristol-Myers Squibb Company (BMY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 77,535,784
  • Shares Outstanding, K 1,632,676
  • Annual Sales, $ 22,561 M
  • Annual Income, $ 4,920 M
  • 60-Month Beta 0.81
  • Price/Sales 3.49
  • Price/Cash Flow 10.99
  • Price/Book 5.57

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate 1.14
  • Number of Estimates 1
  • High Estimate 1.14
  • Low Estimate 1.14
  • Prior Year 0.94
  • Growth Rate Est. (year over year) +21.28%

Price Performance

See More
Period Period Low Period High Performance
1-Month
47.38 +2.02%
on 03/25/19
54.38 -11.11%
on 03/05/19
-1.82 (-3.63%)
since 02/26/19
3-Month
44.30 +9.12%
on 01/03/19
54.38 -11.11%
on 03/05/19
-1.69 (-3.38%)
since 12/26/18
52-Week
44.30 +9.12%
on 01/03/19
63.75 -24.17%
on 03/29/18
-15.06 (-23.75%)
since 03/26/18

Most Recent Stories

More News
Bristol-Myers Squibb (BMY) Outpaces Stock Market Gains: What You Should Know

Bristol-Myers Squibb (BMY) closed the most recent trading day at $48.36, moving +1.83% from the previous trading session.

BMY : 48.34 (+1.79%)
Celgene (CELG) Submits NDA for MS Drug to FDA for Review

Celgene (CELG) progresses with the development of its MS candidate, as it submits an application for the same to the FDA.

CELG : 89.20 (+1.46%)
BLUE : 152.81 (+4.51%)
BMY : 48.34 (+1.79%)
BIIB : 232.91 (+5.74%)
Cancer Biology Clinical Research Seeking Answers at Cellular Level

Research for the cure for cancer has become this generation's version of President John F. Kennedy's May 25, 1961 proclamation to "Landing a man on the Moon and returning him safely". Much money and effort...

CPRX : 5.06 (-3.44%)
CCXI : 12.15 (-0.08%)
MBRX : 1.20 (-6.26%)
SEEL : 2.97 (+6.07%)
BMY : 48.34 (+1.79%)
J&J Files Application for Darzalex Label Expansion in Europe

J&J (JNJ) seeks an approval for Darzalex combo pertaining to the newly diagnosed, transplant-ineligible multiple myeloma patient population in the EU.

CELG : 89.20 (+1.46%)
JNJ : 138.57 (+1.43%)
RHHBY : 34.2800 (+1.33%)
BMY : 48.34 (+1.79%)
Bristol-Myer Sqb (BMY) Approaches New Downside Target of $47.55

Bristol-Myer Sqb (NYSE:BMY) has opened bearishly below the pivot of $48.46 today and has reached the first level of support at $47.85. Analysts will be watching for a cross of the next downside pivot...

BMY : 48.34 (+1.79%)
Report: Developing Opportunities within Bristol-Myers Squibb, AutoNation, FirstEnergy, Charles River Laboratories International, Yum! Brands, and AGNC Investment -- Future Expectations, Projections Moving into 2019

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Bristol-Myers Squibb Company (NYSE:BMY),...

YUM : 98.75 (-0.22%)
AGNC : 18.09 (+0.78%)
CRL : 143.20 (+0.60%)
AN : 34.33 (+0.97%)
BMY : 48.34 (+1.79%)
FE : 42.00 (+0.33%)
Bristol-Myers Squibb Board of Directors Sends Letter to Shareholders Highlighting the Compelling Strategic and Financial Rationale of the Celgene Transaction; Company Provides Additional Investor Materials

Bristol-Myers Squibb Company's (NYSE:BMY) Board of Directors today sent an open letter to the Company's shareholders regarding the previously announced definitive merger agreement with Celgene...

CELG : 89.20 (+1.46%)
CELGZ : 1.16 (+0.50%)
BMY : 48.34 (+1.79%)
Why Bristol-Myers Squibb (BMY) is a Great Dividend Stock Right Now

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Bristol-Myers Squibb (BMY) have what it takes? Let's find out.

BMY : 48.34 (+1.79%)
Next Support Level for Bristol-Myer Sqb (BMY) is $48.74

Shares of Bristol-Myer Sqb (NYSE:BMY) opened today below their pivot of $49.04 and have already reached the first level of support at $48.92. Analysts will be watching for a cross of the next downside...

BMY : 48.34 (+1.79%)
Merck's Keytruda Picks Up Pace in Thriving Anti-PD-L1 Market

Merck's (MRK) Keytruda is rapidly gaining strength as a key contributor to the company's top line. The Keytruda development program is also progressing well.

AZN : 42.94 (+0.92%)
MRK : 82.92 (+0.69%)
PFE : 42.42 (+1.27%)
BMY : 48.34 (+1.79%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade BMY with:

Business Summary

Bristol-Myers Squibb is a differentiated company, led by their unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. They work every day to deliver innovative medicines for patients with serious...

See More

Key Turning Points

2nd Resistance Point 48.84
1st Resistance Point 48.59
Last Price 48.34
1st Support Level 47.94
2nd Support Level 47.54

See More

52-Week High 63.75
Fibonacci 61.8% 56.32
Fibonacci 50% 54.03
Fibonacci 38.2% 51.73
Last Price 48.34
52-Week Low 44.30

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar